vs
Adaptive Biotechnologies Corp（ADPT）与AGENUS INC（AGEN）财务数据对比。点击上方公司名可切换其他公司
Adaptive Biotechnologies Corp的季度营收约是AGENUS INC的2.1倍（$71.7M vs $34.2M）。Adaptive Biotechnologies Corp净利率更高（-18.9% vs -31.0%，领先12.1%）。Adaptive Biotechnologies Corp同比增速更快（51.0% vs 27.5%）。过去两年Adaptive Biotechnologies Corp的营收复合增速更高（30.8% vs 10.5%）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
Agenus Inc.是一家总部位于美国马萨诸塞州列克星敦的生物技术公司，核心业务聚焦免疫治疗领域，尤其专注于利用人体免疫系统控制或治愈癌症的肿瘤免疫治疗。公司目前正在研发检查点调节剂、个性化抗癌疫苗，以及可适配多种疫苗的免疫佐剂，其中检查点调节剂作为当前进展迅速的方向，早期产品已为患者带来突破性临床获益。
ADPT vs AGEN — 直观对比
营收规模更大
ADPT
是对方的2.1倍
$34.2M
营收增速更快
ADPT
高出23.6%
27.5%
净利率更高
ADPT
高出12.1%
-31.0%
两年增速更快
ADPT
近两年复合增速
10.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $34.2M |
| 净利润 | $-13.6M | $-10.6M |
| 毛利率 | 74.6% | — |
| 营业利润率 | -17.8% | 42.1% |
| 净利率 | -18.9% | -31.0% |
| 营收同比 | 51.0% | 27.5% |
| 净利润同比 | 59.7% | 77.3% |
| 每股收益（稀释后） | $-0.08 | $0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADPTAGEN
| Q4 25 | $71.7M | $34.2M | ||
| Q3 25 | $94.0M | $30.2M | ||
| Q2 25 | $58.9M | $25.7M | ||
| Q1 25 | $52.4M | $24.1M | ||
| Q4 24 | $47.5M | $26.8M | ||
| Q3 24 | $46.4M | $25.1M | ||
| Q2 24 | $43.2M | $23.5M | ||
| Q1 24 | $41.9M | $28.0M |
净利润ADPTAGEN
| Q4 25 | $-13.6M | $-10.6M | ||
| Q3 25 | $9.5M | $63.9M | ||
| Q2 25 | $-25.6M | $-30.0M | ||
| Q1 25 | $-29.9M | $-26.4M | ||
| Q4 24 | $-33.7M | $-46.8M | ||
| Q3 24 | $-32.1M | $-67.2M | ||
| Q2 24 | $-46.2M | $-54.8M | ||
| Q1 24 | $-47.5M | $-63.5M |
毛利率ADPTAGEN
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | 97.9% | ||
| Q2 25 | 69.4% | 99.1% | ||
| Q1 25 | 67.6% | 99.4% | ||
| Q4 24 | 62.0% | 99.6% | ||
| Q3 24 | 64.1% | 99.4% | ||
| Q2 24 | 55.3% | 99.5% | ||
| Q1 24 | 56.9% | 99.6% |
营业利润率ADPTAGEN
| Q4 25 | -17.8% | 42.1% | ||
| Q3 25 | 10.9% | -15.0% | ||
| Q2 25 | -42.5% | -65.0% | ||
| Q1 25 | -56.4% | -55.3% | ||
| Q4 24 | -71.3% | -96.5% | ||
| Q3 24 | -70.3% | -125.5% | ||
| Q2 24 | -109.6% | -128.4% | ||
| Q1 24 | -116.5% | -117.4% |
净利率ADPTAGEN
| Q4 25 | -18.9% | -31.0% | ||
| Q3 25 | 10.2% | 211.4% | ||
| Q2 25 | -43.5% | -116.8% | ||
| Q1 25 | -56.9% | -109.6% | ||
| Q4 24 | -71.0% | -174.4% | ||
| Q3 24 | -69.1% | -267.7% | ||
| Q2 24 | -107.0% | -233.1% | ||
| Q1 24 | -113.5% | -226.6% |
每股收益（稀释后）ADPTAGEN
| Q4 25 | $-0.08 | $0.09 | ||
| Q3 25 | $0.06 | $1.94 | ||
| Q2 25 | $-0.17 | $-1.00 | ||
| Q1 25 | $-0.20 | $-1.03 | ||
| Q4 24 | $-0.22 | $-1.95 | ||
| Q3 24 | $-0.22 | $-3.08 | ||
| Q2 24 | $-0.31 | $-2.52 | ||
| Q1 24 | $-0.33 | $-3.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $3.0M |
| 总债务越低越好 | — | $44.7M |
| 股东权益账面价值 | $218.8M | $-271.1M |
| 总资产 | $512.7M | $226.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ADPTAGEN
| Q4 25 | $70.5M | $3.0M | ||
| Q3 25 | $55.0M | $3.5M | ||
| Q2 25 | $43.2M | $9.5M | ||
| Q1 25 | $50.6M | $18.5M | ||
| Q4 24 | $47.9M | $40.4M | ||
| Q3 24 | $38.1M | $44.8M | ||
| Q2 24 | $59.8M | $93.7M | ||
| Q1 24 | $71.2M | $52.9M |
总债务ADPTAGEN
| Q4 25 | — | $44.7M | ||
| Q3 25 | — | $34.2M | ||
| Q2 25 | — | $33.9M | ||
| Q1 25 | — | $33.6M | ||
| Q4 24 | — | $33.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADPTAGEN
| Q4 25 | $218.8M | $-271.1M | ||
| Q3 25 | $204.4M | $-274.1M | ||
| Q2 25 | $179.7M | $-354.6M | ||
| Q1 25 | $190.4M | $-341.8M | ||
| Q4 24 | $202.7M | $-326.4M | ||
| Q3 24 | $223.8M | $-292.3M | ||
| Q2 24 | $241.6M | $-241.3M | ||
| Q1 24 | $274.9M | $-201.4M |
总资产ADPTAGEN
| Q4 25 | $512.7M | $226.8M | ||
| Q3 25 | $490.6M | $233.9M | ||
| Q2 25 | $496.6M | $185.2M | ||
| Q1 25 | $510.9M | $200.2M | ||
| Q4 24 | $539.4M | $226.3M | ||
| Q3 24 | $558.5M | $238.5M | ||
| Q2 24 | $584.9M | $292.4M | ||
| Q1 24 | $620.3M | $256.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $-16.6M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | — |
| 自由现金流率自由现金流/营收 | 2.0% | — |
| 资本支出强度资本支出/营收 | 0.9% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-48.9M | — |
8季度趋势，按日历期对齐
经营现金流ADPTAGEN
| Q4 25 | $2.1M | $-16.6M | ||
| Q3 25 | $-7.1M | $-14.7M | ||
| Q2 25 | $-12.4M | $-20.2M | ||
| Q1 25 | $-28.5M | $-25.6M | ||
| Q4 24 | $-12.5M | $-28.7M | ||
| Q3 24 | $-27.1M | $-53.3M | ||
| Q2 24 | $-17.3M | $-38.2M | ||
| Q1 24 | $-38.4M | $-38.2M |
自由现金流ADPTAGEN
| Q4 25 | $1.4M | — | ||
| Q3 25 | $-7.5M | — | ||
| Q2 25 | $-13.1M | $-20.2M | ||
| Q1 25 | $-29.7M | $-25.6M | ||
| Q4 24 | $-12.6M | $-28.7M | ||
| Q3 24 | $-27.4M | $-53.3M | ||
| Q2 24 | $-19.0M | $-38.6M | ||
| Q1 24 | $-39.9M | $-38.2M |
自由现金流率ADPTAGEN
| Q4 25 | 2.0% | — | ||
| Q3 25 | -8.0% | — | ||
| Q2 25 | -22.2% | -78.7% | ||
| Q1 25 | -56.7% | -106.5% | ||
| Q4 24 | -26.5% | -107.0% | ||
| Q3 24 | -59.0% | -212.2% | ||
| Q2 24 | -44.1% | -164.4% | ||
| Q1 24 | -95.2% | -136.5% |
资本支出强度ADPTAGEN
| Q4 25 | 0.9% | 0.0% | ||
| Q3 25 | 0.4% | 0.0% | ||
| Q2 25 | 1.1% | 0.0% | ||
| Q1 25 | 2.4% | 0.0% | ||
| Q4 24 | 0.2% | 0.3% | ||
| Q3 24 | 0.7% | 0.0% | ||
| Q2 24 | 4.0% | 2.0% | ||
| Q1 24 | 3.6% | 0.1% |
现金转化率ADPTAGEN
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | -0.23× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
AGEN
暂无分部数据
